The General Hospital of Central theater Command
Wuhan, Hubei, 430070, China
NCT Number: NCT01108120
* Diabetic foot ulcers (DFU) are one of the chronic consequences of diabetes which constitute the most important cause of non-traumatic amputation of the inferior limbs. Patients with diabetes are 22 times more likely to have foot ulceration or gangrene than nondiabetics,while foot ulceration precedes 85% of lower-extremity amputation. * Three factors combine to promote tissue necrosis in diabetic feet: ischemia, neuropathy and trauma. Among them, ischemia peripheral arterial disease may play the important roles in the development of DFU. Moreover, diffuse vascular disease is the main characteristics, and thus it becomes difficult for treatment by using arterial bypass or balloon angioplasty. Therefore, we hypothesized that continuous arterial thrombolysis may be an effective therapy in diabetic foot. The purpose of this study is to investigate the effectiveness and safety of continuous intra-femoral artery injection of urokinase by micro-artery-pump in diabetic ulcers.
Looking for future studies?
Notify Me30 year–80 year
All sexes
Interventional
Phase 2
Wuhan, Hubei, 430070, China
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Firstly, 20 0000 u urokinase is injected to the diseased foot via catheter. Then, continuous injection of urokinase via femoral artery by a artery mini-pump (100 ml 0.9% sodium chloride + 100 0000 unit urokinase at a rate of 4 ml per hour) is taken for 7 - 9 days.
All patients receive an intravenous injection of prostaglandin E1 20 ug per day during hospitalization period.
Time frame: < half a year
During hospitalization, the healing rate of foot ulcers is observed.
Time frame: 8 years
During the 8 years of follow up period, recurrence rate of diabetic foot ulcers are observed at 1, 4, 8 year.
Time frame: 8 years
During the follow up period of 8 years, the cardiovascular events, death from all causes are observed at 1, 4 and 8 year.
Xiang Guang-da
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07737184
Cardiovascular Diseases, Diabetes Complications
Ostrava, Czechia
View Trial DetailsNCT06319287
Cardiovascular Diseases, Diabetes Complications
Blue Ash, Ohio, United States
View Trial DetailsNCT05579743
Cardiovascular Diseases, Diabetes Complications
Baltimore, Maryland, United States
View Trial DetailsNCT05094037
Cardiovascular Diseases, Diabetes Complications
Chicago, Illinois, United States
View Trial Details